Nanogenics Overview

  • Year Founded
  • 2011

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 4

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $311K

  • Investors
  • 3

Nanogenics General Information

Description

Developer of a synthetic peptide nanoparticle product designed to target efferent cell types and deliver different payloads. The company's product acts as a custom-built delivery system that can be modified to mimic natural viruses, but bypasses the many problems of viral delivery, enabling clients to obtain higher delivery rates and specificity than traditional liposomal vectors.

Contact Information

Website
www.nanogenics.co.uk
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • Ettrick Riverside, Dunsdale Road
  • Selkirk TD7 5EB
  • Scotland, United Kingdom
Primary Industry
Drug Delivery
Other Industries
Other Healthcare Technology Systems
Acquirer
Thalia Therapeutics
Vertical(s)
Nanotechnology, Life Sciences
Corporate Office
  • Ettrick Riverside, Dunsdale Road
  • Selkirk TD7 5EB
  • Scotland, United Kingdom

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Nanogenics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Merger/Acquisition 28-Sep-2023 $311K Completed Generating Revenue
4. Grant 01-Nov-2019 Completed Generating Revenue
3. Merger/Acquisition 19-Jul-2018 Completed Generating Revenue
2. Early Stage VC Completed Generating Revenue
1. University Spin-Out 17-May-2011 Completed Startup
To view Nanogenics’s complete valuation and funding history, request access »

Nanogenics Patents

  • 10

    Total Documents Applications and Grants

  • Total Patents Families

  • 6

    Granted

  • 1

    Pending

  • Expiring in next 12 mo

Nanogenics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
GB-202409471-D0 Inhibition of myocardin-related transcription factor b (mrtf-b) Inactive 01-Jul-2024
CA-3016614-A1 Lipids and complexes for the delivery of biologically-active material to cells Pending 11-Mar-2016
US-11098006-B2 Lipids and complexes for the delivery of biologically-active material to cells Inactive 11-Mar-2016
US-20190084923-A1 Lipids and complexes for the delivery of biologically-active material to cells Active 11-Mar-2016
US-20100184831-A1 Materials and complexes for the delivery of biologically-active materials to cells Active 30-May-2006 A61K9/1271
To view Nanogenics’s complete patent history, request access »

Nanogenics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Nanogenics Former Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds
Scottish Enterprise Growth/Expansion Minority
TRICAPITAL Angel Investors Angel Group Minority
UCL Ventures University Minority
To view Nanogenics’s complete investors history, request access »

Ready to get started?

Request a free trial

Nanogenics FAQs

  • When was Nanogenics founded?

    Nanogenics was founded in 2011.

  • Where is Nanogenics headquartered?

    Nanogenics is headquartered in Selkirk, United Kingdom.

  • What is the size of Nanogenics?

    Nanogenics has 4 total employees.

  • What industry is Nanogenics in?

    Nanogenics’s primary industry is Drug Delivery.

  • Is Nanogenics a private or public company?

    Nanogenics is a Private company.

  • What is the current valuation of Nanogenics?

    The current valuation of Nanogenics is .

  • What is Nanogenics’s current revenue?

    The current revenue for Nanogenics is .

  • Who are Nanogenics’s investors?

    Scottish Enterprise, TRICAPITAL Angel Investors, and UCL Ventures have invested in Nanogenics.

  • When was Nanogenics acquired?

    Nanogenics was acquired on 28-Sep-2023.

  • Who acquired Nanogenics?

    Nanogenics was acquired by Thalia Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process